Comparably Awards

BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson’s disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. read more

This company is accepting feedback from verified employees EMPLOYEE PARTICIPANTS: 180

TOTAL RATINGS: 5197

CEO: SETH ETTENBERG, PH.D.

SETH ETTENBERG, PH.D. BlueRock Therapeutics CEO Rating

BlueRock Therapeutics' CEO, SETH ETTENBERG, PH.D., has 180 employee ratings and a score of 89/100, placing them in the Top 5% of similar size companies on Comparably with 201-500 Employees and Top 5% of other companies in Boston. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that females at BlueRock Therapeutics rate SETH ETTENBERG, PH.D. higher than males, giving the CEO a score of 90/100.

Last updated months ago.

Where This Score Ranks BlueRock Therapeutics' CEO Rating

TOP
5%
In the Top 5% of 2013 Similar Sized Companies on Comparably
TOP
5%
In the Top 5% of 270 Nearby Companies in Boston
1st
1st place versus 4 competitors rated on Comparably

Jul

Aug

Jan

Nov

Dec

A+89 / 100

Jan

BlueRock Therapeutics CEO SETH ETTENBERG, PH.D. Bio

Seth Ettenberg, PhD, is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2020 - 2021. Prior to joining BlueRock, Seth was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. Previously, Seth headed the Cambridge Site of Novartis’ Oncology Biotherapeutics, leading strategy, innovation, and implementation of drug development projects of Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute.

Who Ranks BlueRock Therapeutics' CEO Rating the Highest?

Department - HR 99/100

Ethnicity - African American/Black 95/100

Department - Admin 94/100

Who Ranks BlueRock Therapeutics' CEO Rating the Lowest?

Ethnicity - Other 83/100

Department - R&D 87/100

Experience - 1 to 3 Years 87/100

BlueRock Therapeutics CEO SETH ETTENBERG, PH.D. At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at BlueRock Therapeutics.

Based on 180 ratings, SETH ETTENBERG, PH.D. ranks right above Intellia Therapeutics' CEO, John Leonard.

BlueRock Therapeutics' CEO is highly regarded by the HR department, African American/Black employees, and the Admin department. However, the R&D department and employees with 1 to 3 Years experience have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.